BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/2/2015 12:19:00 PM | Browse: 1523 | Download: 1611
 |
Received |
|
2014-05-18 16:10 |
 |
Peer-Review Started |
|
2014-05-18 22:44 |
 |
To Make the First Decision |
|
2014-06-06 11:02 |
 |
Return for Revision |
|
2014-06-16 11:10 |
 |
Revised |
|
2014-06-22 22:48 |
 |
Second Decision |
|
2014-09-10 13:39 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2014-09-10 14:01 |
 |
Articles in Press |
|
2014-09-10 14:01 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2014-10-27 15:03 |
 |
Publish the Manuscript Online |
|
2014-11-05 09:07 |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Minireviews |
Article Title |
Lipid-lowering agents in the management of nonalcoholic fatty liver disease
|
Manuscript Source |
Invited Manuscript |
All Author List |
Konstantinos Tziomalos |
Funding Agency and Grant Number |
|
Corresponding Author |
Konstantinos Tziomalos, MD, PhD, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Kiriakidi 1, 54636 Thessaloniki, Greece. ktziomalos@yahoo.com
|
Key Words |
Nonalcoholic fatty liver disease; Statins; Fibrates; Ezetimibe; Colesevelam; Omega-3 fatty acids; Nicotinic acid; Cardiovascular disease; Transaminases; Nonalcoholic steatohepatitis |
Core Tip |
Accumulating data suggest that statins are safe in patients with nonalcoholic fatty liver disease (NAFLD) and that they reduce the increased cardiovascular morbidity of this population. However, it is still unclear whether statins are also useful as a treatment for NAFLD per se, since there are very limited and conflicting data on their effects on liver histology. There is also very scarce evidence regarding the safety and efficacy of other lipid-lowering agents in patients with NAFLD.
|
Publish Date |
2014-11-05 09:07 |
Citation |
Tziomalos K. Lipid-lowering agents in the management of nonalcoholic fatty liver disease. World J Hepatol 2014; 6(10): 738-744 |
URL |
http://www.wjgnet.com/1948-5182/full/v6/i10/738.htm |
DOI |
http://dx.doi.org/10.4254/wjh.v6.i10.738 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345